← Eichor
Study identifier: NCT06599658 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

Condition: COVID 19 · Influenza · Rheumatoid Arthritis (RA)  ·  Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

PhasePhase 2
Planned participants660
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1. Is co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recommended COVID-19 booster dose non-inferior in inducing a 1-month peak protective humoral response against COVID-19, compared to a strategy of sequential administration of COVID-19 booster dose followed by seasonal IIV given one month later? 2. Is the administration of the most up-to-date recommended COVID-19 booster doses at 3-month intervals superior at maintaining a longer term protective humoral immune response, compared to booster doses administered at 6-month intervals? Researchers will compare (1) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 3-month interval, (2) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 3-month interval, (3) COVID-19 and Influenza vaccines administered at Day 0 + COVID-19 Booster at a 6-month interval, and (4) COVID-19 vaccine administered at Day 0 and Influenza vaccine administered at Day 28 + COVID-19 Booster at a 6-month interval to see if median neutralization capacity of patient sera is non-inferior in the co- vs. sequential administration arms at 1-month afte…

This description comes directly from the study's public registry record.

Talk to the study team

Ruth Sapir-Pichhadze, B.Med.Sc, MD, MSc, PhD, FRCPC  ·  5149341934  ·  ruth.sapir-pichhadze.med@ssss.gouv.qc.ca

Always discuss trial participation with your own doctor first.

Locations (3)

Maisonneuve -Rosemont InstallationMontreal, Quebec, CanadaRecruiting
Centre hospitalier de l'Université de Montréal (CHUM)Montreal, Quebec, CanadaRecruiting
Research Institute of McGill University Health CentreMontreal, Quebec, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06599658